Skip to main content
NewslettersWatchlist

Bausch Lomb Corporation(BLCO-T)
TSX

Today's Change
Real-Time Last Update
Day Low27.35
Day High27.41
Open:27.35
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Business Wire
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
Business Wire
Bausch + Lomb Announces Third-Quarter 2024 Results
The Globe and Mail
Tuesday’s analyst upgrades and downgrades
Business Wire
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
Business Wire
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30
Business Wire
Bausch + Lomb Launches Opal™ Digital Marketplace in the United States
The Globe and Mail
Thursday’s analyst upgrades and downgrades
Baystreet
Stocks in play: Bausch + Lomb Corporation
The Globe and Mail
Monday’s analyst upgrades and downgrades
AI-generated - The Globe and Mail
Bausch & Lomb: Top 10 Undervalued Growth Stocks on TSX (BLCO)
Baystreet
Stocks in play: Bausch + Lomb Corporation
AI-generated - The Globe and Mail
Bausch & Lomb: Top 10 Undervalued Growth Stocks on TSX (BLCO)
AI-generated - The Globe and Mail
Bausch & Lomb: Top 10 Undervalued Growth Stocks on TSX (BLCO)
The Globe and Mail
Thursday’s analyst upgrades and downgrades
The Globe and Mail
Monday’s analyst upgrades and downgrades
Baystreet
Stocks in play: Bausch + Lomb Corporation
AI-generated - The Globe and Mail
Bausch & Lomb: Top 10 Undervalued Growth Stocks on TSX (BLCO)
Baystreet
Stocks in play: Bausch + Lomb Corporation
The Globe and Mail
Thursday’s analyst upgrades and downgrades
Baystreet
Stocks in play: Bausch + Lomb Corporation
The Globe and Mail
Friday’s analyst upgrades and downgrades
The Globe and Mail
Why this bargain-hunting money manager is buying Fairfax India and Tim Hortons in China

Profile

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.